Streetbeat News

Products Services

RVMD

Revolution Medicines, Inc. (NASDAQ:RVMD) shares surged after announcing the publication of several peer-reviewed research papers on RMC-6236 and RMC-7977, showing promising preclinical and preliminary clinical data. The stock hit a new 52-week high of $37.50, trading above its 50-day moving average.

Portfolio Pulse from Erica Kollmann

April 10, 2024 | 4:20 pm

ADIL

ASTI

JAGX

MRIN

VIAO

VLD

U.S. stocks traded lower, with the Dow Jones index falling over 500 points. Energy shares fell by 0.3%, while real estate shares tumbled by 4.1%. U.S. crude oil inventories increased more than expected. Marin Software's shares jumped 146% after announcing upgrades with Microsoft Advertising. Adial Pharmaceuticals surged 66% following a positive article on AD04. Jaguar Health gained 37% after a successful stockholder meeting. VIA optronics, Ascent Solar Technologies, and Velo3D saw significant drops after various announcements.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 4:15 pm

RVMD

Revolution Medicines' stock is trading higher following the announcement of a research paper publication on RMC-6236 in Cancer Discovery.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 4:12 pm

APRE

Aprea Therapeutics announced presentations on APR-1051 and ATRN-119 at AACR Annual Meeting 2024, highlighting pre-clinical and clinical updates. APR-1051, a WEE1 kinase inhibitor, shows potential for treating Cyclin E-overexpressing cancers with minimal off-target effects and low cardiotoxicity. ATRN-119, an ATR inhibitor, demonstrated safety and preliminary clinical benefit in an ongoing study. The company plans to initiate a Phase 1 trial for APR-1051 in June 2024.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 4:02 pm

ORGS

Germfree and Orgenesis Inc. (NASDAQ:ORGS) announced an asset purchase and strategic partnership to revolutionize cell and gene therapy production, aiming for global accessibility and affordability. The collaboration will leverage Germfree's modular cleanroom technology and Orgenesis' cell and gene therapy processes to reduce production costs and enable broader adoption of these treatments. The partnership will co-market Orgenesis' decentralized Octomera service platform and its mobile processing units globally, focusing on immuno-oncology and meeting growing demand.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 4:01 pm

TSLA

Tesla Inc's Cybertruck, released last year, has sparked speculation about a bigger battery due to a teaser video showing empty space in its battery pack. A lead engineer's comment and Elon Musk's mention of a 'range extender' suggest future versions may have extended range capabilities. This positions the Cybertruck as a versatile option for various transport needs.

Portfolio Pulse from Benzinga EV Insights

April 10, 2024 | 3:52 pm

BRETT

SHIBUSD

TOSHI

Crypto traders CryptoDan and Crashius Clay shared tips on finding 100X meme coins, emphasizing contrarian strategies and strong conviction. Crashius Clay highlighted his success with BRETT, while CryptoDan is bullish on TOSHI. Their strategies include buying early, selling into hype, and maintaining a reserve fund. The podcast also touched on the potential of meme coins and Bitcoin in the institutional space, with a future event by Benzinga to explore these topics further.

Portfolio Pulse from Ivan Crnogatić

April 10, 2024 | 3:50 pm

AAPL

GLD

SPY

USO

New data indicates higher-than-expected inflation, suggesting a potential pullback in the stock market, though the bull market remains intact. The Arora Report plans to buy on the pullback, advising investors to increase cash holdings and adjust hedges. Early trade shows negative money flows in major tech stocks and ETFs, with the momo crowd buying stocks and gold, while smart money sells. Oil sees a build in inventories, and Bitcoin drops on the inflation news, challenging its status as an inflation hedge.

Portfolio Pulse from The Arora Report

April 10, 2024 | 3:36 pm

LLY

The FDA has approved Loxo Oncology at Eli Lilly's drug, Retevmo, for treatment, as reported by Reuters citing the FDA's website.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 3:31 pm

Ford shares are trading lower due to overall market weakness following the release of March inflation data. Additionally, Ford announced a recall of 42,652 vehicles, which may also be contributing to the stock's decline.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 3:29 pm